Manufacturing Scale-Up: Ensuring Consistent Antibody Function with Systems Serology
June 12, 2025
Summary: During the scale-up of SARS-CoV-2 monoclonal antibody production, shifts in glycosylation patterns were observed due to changes in manufacturing conditions. Using Systems Serology, SeromYx confirmed that these changes did not affect antibody function, demonstrating the platform’s value in maintaining therapeutic consistency during clinical development.
The World Vaccine Congress Europe 2025
Festival of Biologics
The Fc-Mediated Effector Function Summit
Authors: Atyeo et al. Immunity (2020)
Authors: Kaplonek P, et al. Sci Transl Med. 2022 May 18;14(645):eabm2311.
Authors: Hawman, David W. et al. eBioMedicine, Volume 115, 105698
Authors: P. Hsueh, M. Friedman, S. Jatiani (2024) Application Note
